Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Motexafin lutetium (Pharmacyclics).

P F Yeung1

  • 1College of Pharmacy, Dalhousie University, Burbridge Building, Halifax, NS B3H-3J5, Canada. pollen.yeung@dal.ca

Idrugs : the Investigational Drugs Journal
|July 19, 2005
PubMed
Summary

Pharmacyclics is investigating motexafin lutetium for multiple conditions. Antrin targets restenosis, Lutrin targets cancer, and Optrin targets age-related macular degeneration (AMD).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender differences in exercise and recovery blood pressure responses in normal volunteers given diltiazem.

Journal of clinical pharmacologyยท1995
See all related articles

Area of Science:

  • Photodynamic therapy
  • Vascular disease
  • Oncology
  • Ophthalmology

Background:

  • Pharmacyclics is developing motexafin lutetium, a photosensitizer, for various medical applications.
  • The compound is being investigated under different brand names for distinct therapeutic areas.

Purpose of the Study:

  • To evaluate Antrin (motexafin lutetium) photoangioplasty for peripheral artery disease (PAD) and restenosis prevention.
  • To assess Lutrin (motexafin lutetium) for cancer treatment, including breast cancer.
  • To determine the efficacy of Optrin (motexafin lutetium) in photodynamic therapy for age-related macular degeneration (AMD).

Main Methods:

  • Phase II multicenter, randomized, controlled study for Antrin in 375 PAD patients.
  • Phase II and IIb trials for Lutrin in breast cancer patients.
  • Phase II dose-ranging study for Optrin in AMD patients.

Main Results:

  • Preliminary results from Optrin's phase II study for AMD have been reported.
  • Ongoing clinical trials are evaluating Antrin for PAD and Lutrin for various cancers.

Conclusions:

  • Motexafin lutetium shows potential in treating restenosis, atherosclerotic plaques, cancer, and AMD.
  • Further clinical evaluation is ongoing for these indications.

Related Experiment Videos